Phase 3 clinical trial

ECTRIMS 2023: Under-the-skin Ocrevus found to be powerful in MS

A new under-the-skin formulation of Ocrevus (ocrelizumab) ā€” administered in 10 minutes ā€” is at least as effective as the approved intravenous, or into-the-vein, formulation among people with multiple sclerosis (MS), according to new clinical trial data. Most people given either the new subcutaneous formulation or the intravenous…

Biosimilar Comparable in Safety, Efficacy to Tysabri in Phase 3 Trial

PB006, a biosimilar to Biogenā€™s approved treatment Tysabri (natalizumab), showed similar safety and efficacy as the original medication in peopleĀ with relapsing-remitting MS (RRMS), according to data from a Phase 3 clinical trial. “The Antelope trial reported equivalence between [PB006 and Tysabri] treatment across efficacy, safety, and secondary…

Stem Cell Program That Treated Selma Blair Closes Its Doors

Richard Burt, MD, the chief of Northwestern Medicine’s immunotherapy for autoimmune diseases division, is taking a sabbatical, and the stem cell program he has headed for many years, which treated a number of people with MS, is shutting down. Burt headed a Phase 3 clinical trial…

MedDay Raises $38.5M to Finance Phase 3 Trial Targeting Progressive MS

MedDay SASĀ recently announced that it has raised ā‚¬34 million, about $38.5 million, in a Series B financing round. The moneyĀ will enable the company to lead a confirmatory Phase 3 clinical trial, called SPI2, in the United StatesĀ toĀ assess itsĀ lead candidate, MD1003, as a treatment for progressive multiple sclerosis (MS). MedDayĀ concluded…